mTOR — The Cell's Central Nutrient-Sensing Hub
Placeholder: mTOR integrates nutrient, energy, and growth-factor cues into one growth decision.
- mTORC1: Complex (Placeholder: primary longevity-relevant complex)
- 4: Key inputs (Placeholder: amino acids, energy, growth factors, oxygen)
- Yeast→Human: Conservation (Placeholder: pathway conserved across eukaryotes)
- 1990s: Discovery era (Placeholder: TOR first identified in yeast)
What mTORC1 senses
Placeholder: amino acid and energy sensing inputs to mTORC1.
Growth vs. maintenance trade-off
Placeholder: high mTOR activity favors growth over cellular upkeep.
Why nutrient sensing links to aging
Placeholder: chronic nutrient-sensing overactivation is tied to aging.
Placeholder key insight: mTOR sits at the crossroads of growth and longevity signaling.
Rapamycin Binding and Allosteric mTOR Inhibition
Placeholder: rapamycin forms a ternary complex with FKBP12 to inhibit mTORC1.
- FKBP12: Binding partner (Placeholder: immunophilin co-receptor)
- Easter Island: Origin (Placeholder: discovered in soil bacterium)
- Allosteric: Inhibition type (Placeholder: partial, complex-selective)
- Immunosuppressant: Clinical use (Placeholder: originally approved for transplant)
Ternary complex formation
Placeholder: rapamycin-FKBP12 docks onto the FRB domain of mTOR.
mTORC1 vs mTORC2 selectivity
Placeholder: rapamycin preferentially inhibits mTORC1 acutely.
Dose and intermittent dosing strategies
Placeholder: intermittent low-dose regimens aim to limit side effects.
Placeholder key insight: partial, intermittent inhibition may separate longevity benefit from side effects.
Lifespan Extension Across Yeast, Worms, Flies, and Mice
Placeholder: rapamycin extends lifespan in every model organism tested so far.
- ~20-60%: C. elegans extension (Placeholder: worm lifespan studies)
- ~10-25%: Mouse extension (Placeholder: NIA Interventions Testing Program)
- 2004: ITP start year (Placeholder: multi-site mouse aging program)
- Yes: Sex difference (Placeholder: effect size differs by sex)
Yeast and invertebrate studies
Placeholder: earliest lifespan extension evidence came from yeast and worms.
The NIA Interventions Testing Program in mice
Placeholder: multi-cohort mouse studies replicated lifespan extension.
Dose-response and late-life initiation
Placeholder: benefits appear even when treatment starts late in life.
Placeholder key insight: late-onset dosing still extends mouse lifespan meaningfully.
Cellular Maintenance Pathways Activated by mTOR Inhibition
Placeholder: inhibiting mTOR unlocks autophagy and other repair pathways.
- Increased: Autophagy induction (Placeholder: ULK1 complex de-repressed)
- Improved: Proteostasis (Placeholder: reduced misfolded protein burden)
- Enhanced: Mitochondrial quality (Placeholder: mitophagy upregulation)
- Broad: Stress resistance (Placeholder: cross-stressor resilience)
Autophagy and proteostasis activation
Placeholder: autophagy clears damaged cellular components.
Mitochondrial and metabolic effects
Placeholder: mitochondrial turnover and metabolism shift favorably.
Hallmarks of aging addressed
Placeholder: mTOR inhibition touches multiple aging hallmarks at once.
Placeholder key insight: one pathway intersects several hallmarks of aging simultaneously.
From Mice to Humans — Open Questions and Clinical Trials
Placeholder: translating rodent longevity findings to humans remains unproven.
- Few: Human RCTs (aging) (Placeholder: limited long-term human trials)
- Improved: Immune biomarkers (Placeholder: PEARL trial vaccine response)
- Metabolic: Side-effect concerns (Placeholder: glucose and lipid effects)
- Low-Moderate: Confidence level (Placeholder: extrapolation uncertainty)
Human clinical trial landscape
Placeholder: small trials test immune and biomarker endpoints, not lifespan.
Safety and off-target effect concerns
Placeholder: chronic use raises metabolic and immune safety questions.
What would be needed to prove human benefit
Placeholder: long-term randomized trials with aging biomarker endpoints are needed.
Placeholder key insight: human lifespan extension remains a hypothesis, not an established fact.